More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
Read our monthly recap of some of the biggest FDA-related stories that have hit cardiology, including updates related to Cytokinetics, Dexcom and Abiomed.
A neurologist who examined the patient's imaging explained that her brain swelling was so severe in some cases that the folds of the cerebral cortex appeared “merged and squashed.”
A population-level study featuring multi-organ MRI has confirmed that problems in any of three major organs—the heart, brain or liver—tend to co-occur with unfavorable findings in either or both of the other two.
Researchers have identified new details about the link between certain cancer therapies and heart complications. Could their work lead to key improvements in patient care?
Professional consensus supports the use of ultrasound for initial imaging evaluation of patients presenting in the ED with suspected urinary stone disease (USD). However, as of 2018, only 2% of these patients received ultrasound while some 59% had CT.
